Literature DB >> 708643

Plasma clearance and renal excretion of erythrocyte cryoprotectant hydroxyethylated amylopectin.

J M Mishler, E S Parry, A Petrie.   

Abstract

The value of low molecular weight-hydroxyethylated amylopectin (cryo-HES) as an extracellular cryoprotectant has been demonstrated in vitro. It is important that details of the intravascular persistence and urinary excretion be determined to compare with data already available as other grades of HES and with data on transfusion of cryo-HES cryoprotected blood. Following a single 400 ml (14% solution) infusion in man, the intravascular clearance of cryo-HES was well described mathematically by the equation: y = 3.30+6.49e-0.15kappa. The plasma concentration of cryo-HES fell to half its peak value in approximately 9.6 h. Approximately 20% of the total infused cryo-HES was excreted in the urine during the first post-injection hour, and 50% by 72 h. The ESR was not altered significantly by the presence of this material. The present study indicates that cryo-HES is eliminated rapidly and may thus be safe for transfusion to recipients of frozen blood.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 708643     DOI: 10.1111/j.1365-2141.1978.tb03660.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

Review 1.  Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies.

Authors:  Romuald Bellmann; Clemens Feistritzer; Christian J Wiedermann
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

2.  Urinary excretion kinetics of hydroxyethyl starch 350/0.60 in normovolaemic man.

Authors:  J M Mishler; C R Ricketts; E J Parkhouse
Journal:  J Clin Pathol       Date:  1981-04       Impact factor: 3.411

3.  Post-transfusion survival of hydroxyethyl starch 450/0.70 in man: a long-term study.

Authors:  J M Mishler; C R Ricketts; E J Parkhouse
Journal:  J Clin Pathol       Date:  1980-02       Impact factor: 3.411

Review 4.  Clinical pharmacokinetic considerations in the use of plasma expanders.

Authors:  U Klotz; H Kroemer
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.